California Patent of the Month – January 2023

Isla Technologies Inc. is on a mission to revolutionize the treatment of Type 1 Diabetes with their innovative bioartificial pancreas implants. These implants are a combination of living cells and biocompatible materials that can provide automatic and continuous regulation of hormones such as insulin, for patients with Type 1 diabetes.

Type 1 diabetes is a chronic metabolic disorder that affects roughly 10% of the global population, making it one of the most widespread diseases. People with this condition are traditionally insulin-dependent for life and have to deal with the rigors of daily insulin treatments and monitoring their blood sugar levels. However, with Isla Technologies’ bioartificial pancreas implants, patients can have a more reliable means of generating and delivering insulin, reducing their dependence on traditional insulin treatments.

Isla Technologies’ bioartificial pancreas implants offer a unique solution for the treatment of Type 1 diabetes. The implant can be formed into a tubular structure, matching that of a blood vessel, and inserted into a patient’s blood vessel, close to their bloodstream. This allows the cells within the implant to receive adequate oxygenation and nutrient support, and hormones generated by the cells can quickly enter the patient’s bloodstream. The implant may also be made of bio-absorbable materials that gradually degrade and become absorbed in the body, making it unnecessary to retrieve the implant after its use.

When composed of pancreatic islets, the bioartificial pancreas can generate insulin, glucagon, amylin, somatostatin, ghrelin, and/or pancreatic polypeptides in any combination and ratio. They can also be composed of thyroid hormone-producing cells, parathyroid-producing cells, and adrenal hormone-producing cells. With this incredible versatility, the bioartificial pancreas implant is suitably adapted for treating other metabolic disorders as well.

After implantation, the cells within the bioartificial pancreas sense changes in glucose and secrete insulin in response. This design allows the device to function for years, improving patient’s glycemic control and quality of life without them needing to consistently monitor it.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts